Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Rating of "Moderate Buy" from Brokerages

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $63.89.

IRON has been the topic of a number of recent analyst reports. Wells Fargo & Company assumed coverage on Disc Medicine in a research note on Thursday, August 22nd. They issued an "overweight" rating and a $75.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of Disc Medicine in a research note on Monday, September 16th. Wedbush restated an "outperform" rating and set a $57.00 price target on shares of Disc Medicine in a research note on Friday, August 9th. Scotiabank assumed coverage on Disc Medicine in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $62.00 price target on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $85.00 price target on shares of Disc Medicine in a research note on Tuesday, October 15th.

Disc Medicine Stock Performance

Shares of Disc Medicine stock traded up $0.21 during trading on Monday, reaching $50.77. The company's stock had a trading volume of 238,943 shares, compared to its average volume of 347,093. The business's fifty day moving average price is $48.88 and its 200-day moving average price is $41.75. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -15.02 and a beta of 0.59. Disc Medicine has a one year low of $25.60 and a one year high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, topping analysts' consensus estimates of ($1.11) by $0.08. Sell-side analysts anticipate that Disc Medicine will post -4.19 EPS for the current year.

Institutional Investors Weigh In On Disc Medicine

Several large investors have recently modified their holdings of the stock. Amalgamated Bank grew its stake in shares of Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company's stock valued at $26,000 after purchasing an additional 247 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Disc Medicine by 19.5% in the 3rd quarter. SG Americas Securities LLC now owns 4,864 shares of the company's stock worth $239,000 after acquiring an additional 793 shares in the last quarter. Bleakley Financial Group LLC boosted its holdings in shares of Disc Medicine by 23.0% in the 1st quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company's stock worth $285,000 after acquiring an additional 856 shares in the last quarter. TD Asset Management Inc boosted its holdings in shares of Disc Medicine by 3.7% in the 2nd quarter. TD Asset Management Inc now owns 40,732 shares of the company's stock worth $1,836,000 after acquiring an additional 1,468 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Disc Medicine in the 2nd quarter worth approximately $129,000. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.